0.8791 0 (0.01%) | 11-08 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 1.13 | 1-year : | 1.32 |
Resists | First : | 0.97 | Second : | 1.13 |
Pivot price | 0.87 | |||
Supports | First : | 0.85 | Second : | 0.77 |
MAs | MA(5) : | 0.88 | MA(20) : | 0.87 |
MA(100) : | 0.92 | MA(250) : | 1.43 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 68.8 | D(3) : | 62.9 |
RSI | RSI(14): 50.8 | |||
52-week | High : | 3.25 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MLEC ] has closed below upper band by 39.5%. Bollinger Bands are 63.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.89 - 0.9 | 0.9 - 0.9 |
Low: | 0.84 - 0.84 | 0.84 - 0.85 |
Close: | 0.87 - 0.88 | 0.88 - 0.89 |
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.
Sat, 02 Nov 2024
Moolec Becomes First Molecular Farming Company to Achieve USDA A - GuruFocus.com
Thu, 17 Oct 2024
Biotech Wants Vegetarians to Eat Its Peas Spliced With Beef DNA - Bloomberg
Wed, 16 Oct 2024
Moolec Has Received USDA Approval for the First Genetically Modified Pea in History - Via Ritzau
Wed, 02 Oct 2024
Moolec Science Presents Fiscal Year 2024 Annual Business Update - Newswire
Wed, 02 Oct 2024
Moolec Science Presents Fiscal Year 2024 Annual Business Update - StockTitan
Wed, 25 Sep 2024
Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 38 (M) |
Shares Float | 0 (M) |
Held by Insiders | 88.4 (%) |
Held by Institutions | 0.3 (%) |
Shares Short | 138 (K) |
Shares Short P.Month | 143 (K) |
EPS | -0.19 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.18 |
Profit Margin | -130 % |
Operating Margin | -193.1 % |
Return on Assets (ttm) | -19.3 % |
Return on Equity (ttm) | -86.5 % |
Qtrly Rev. Growth | 68.3 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.14 |
EBITDA (p.s.) | -0.22 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -9 (M) |
Levered Free Cash Flow | -20 (M) |
PE Ratio | -4.63 |
PEG Ratio | 0 |
Price to Book value | 4.62 |
Price to Sales | 6 |
Price to Cash Flow | -3.63 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |